Search - tctmd.com

Displaying 81 - 100 of 393

Sort: Relevancy | Date

Presentation TCT 2017

Improving Outcomes in Cardiogenic Shock: Issues the Guidelines Dont Discuss

Presenter: Michael Mooney, Holger Thiele, Venu Menon

October 31, 2017

Presentation TCT 2017

Musings on TMVR Patient Selection Criteria to Date, and Which Patients Should Be Put in TMVR Trials Rather Than Treated Clinically With Current Devices

Presenter: Howard C. Herrmann, Michael J. Mack

October 31, 2017

Presentation TCT 2017

Emerging TMVR 5: Mitraltech - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Francesco Maisano

October 31, 2017

Presentation TCT 2017

Emerging TMVR 4: Corona Valve With Amend Ring - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, David Meerkin

October 31, 2017

Presentation TCT 2017

Emerging TMVR 3: M-Dock - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Maurice Buchbinder

October 31, 2017

Presentation TCT 2017

The Top 10 Quality Metrics for Your Cath Lab

Presenter: J. Dawn Abbott, Sunil V. Rao, Michael A. Kutcher

October 31, 2017

Presentation TCT 2017

Emerging TMVR 2: 4C - Device Description, Critical Appraisal, and Development Plans

Presenter: Howard C. Herrmann, Michael J. Mack, Philippe Genereux

October 31, 2017

Presentation TCT 2017

Established TMVR 6: Caisson - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Mathew Williams

October 31, 2017

Presentation TCT 2017

Established TMVR 5: Highlife - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Nicolo Piazza

October 31, 2017

Presentation TCT 2017

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Vinayak Bapat

October 31, 2017

Presentation TCT 2017

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, David W.M. Muller

October 31, 2017

Presentation TCT 2017

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Anson Cheung

October 31, 2017

Presentation TCT 2017

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, James B. Hermiller Jr.

October 31, 2017

Presentation TCT 2017

Keynote Address: Grand Summary of the Vast TMVR Landscape - Differentiating Features and Outcomes

Presenter: Howard C. Herrmann, Michael J. Mack, Bernard Prendergast

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

TCT 36: Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement

Presenter: Reginald I. Low, Michael J. Rinaldi, Richard Jabbour

October 31, 2017

Presentation TCT 2017

TCT 20: Ten-year Clinical Outcome in Patients With Coronary Chronic Total Occlusions not Revascularized by Percutaneous Coronary Intervention According to Left Ventricle Systolic Function

Presenter: James C. Spratt, R. Michael Wyman, Cosmo Godino, MD

October 31, 2017

Presentation TCT 2017

TCT 4: Prognostic Impact of Nonculprit Chronic Total Occlusions in Infarct-Related Cardiogenic Shock - Results of the Randomized IABP-SHOCK II Trial

Presenter: Rajesh M. Dave, A. Michael Lincoff, Mohammed Saad, MD

October 31, 2017

Presentation TCT 2017

TCT 36: Cerebral Embolic Protection During Transfemoral Aortic Valve Replacement Reduces Death and Stroke Compared to Unprotected Procedure in All Subgroups

Presenter: Reginald I. Low, Michael J. Rinaldi, Julia Seeger

October 31, 2017

Presentation TCT 2017

TCT 3: Outcomes of Left Main Revascularization in Patients With Acute Coronary Syndrome vs Stable Angina: Analysis From the EXCEL Trial

Presenter: Rajesh M. Dave, A. Michael Lincoff, Marc Etienne Jolicoeur

October 31, 2017

Advertisement

Improving Outcomes in Cardiogenic Shock: Issues the Guidelines Dont Discuss

Musings on TMVR Patient Selection Criteria to Date, and Which Patients Should Be Put in TMVR Trials Rather Than Treated Clinically With Current Devices

Emerging TMVR 5: Mitraltech - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 4: Corona Valve With Amend Ring - Device Description, Critical Appraisal, and Development Plans

Emerging TMVR 3: M-Dock - Device Description, Critical Appraisal, and Development Plans

The Top 10 Quality Metrics for Your Cath Lab

Emerging TMVR 2: 4C - Device Description, Critical Appraisal, and Development Plans

Established TMVR 6: Caisson - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 5: Highlife - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 4: Intrepid - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 3: Tendyne - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 2: Tiara - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Established TMVR 1: Cardiaq - Device Description, Strengths and Weaknesses, and Updated Summary Outcomes

Keynote Address: Grand Summary of the Vast TMVR Landscape - Differentiating Features and Outcomes

Long-term Absorb BVS Data Continue to Disappoint

TCT 36: Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement

TCT 20: Ten-year Clinical Outcome in Patients With Coronary Chronic Total Occlusions not Revascularized by Percutaneous Coronary Intervention According to Left Ventricle Systolic Function

TCT 4: Prognostic Impact of Nonculprit Chronic Total Occlusions in Infarct-Related Cardiogenic Shock - Results of the Randomized IABP-SHOCK II Trial

TCT 36: Cerebral Embolic Protection During Transfemoral Aortic Valve Replacement Reduces Death and Stroke Compared to Unprotected Procedure in All Subgroups

TCT 3: Outcomes of Left Main Revascularization in Patients With Acute Coronary Syndrome vs Stable Angina: Analysis From the EXCEL Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content